Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept for nAMD Dosing Regimens Phase IV Study
CTR20180826Phase 4Completed
- Sponsor
- Chengdu Kanghong Biotechnology Co., Ltd.
- Start
- Jun 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of conbercept in exudative macular degeneration, sponsored by Chengdu Kanghong Biotechnology Co., Ltd.. Started Jun 2018; status: completed.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20180826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180826.